Celsion Corporation (NASDAQ:CLSN) Looks Forwards With DIGNITY

1024

Dallas, Texas 01/10/2014 (FINANCIALSTRENDS) – Celsion Corporation (NASDAQ:CLSN), the U.S. biopharmaceutical company, with a major interest in developing top-line cancer-treatment, continues to innovate in the industry as it seeks new solutions for, non-treatable cancers and for those forms where no efficacy-plus drug is yet available.

Celsion Corporation (NASDAQ:CLSN) main-line drug ThermoDox is used in the treatment of hepatocellular carcinoma, one of the most common types of liver cancer. The drug is in the phase III study in September, it last showed, that there was no progression in single lesions nor in mortality.

Celsion Corporation (NASDAQ:CLSN) ThermoDox is effective in managing the single lesion, when it was used in combination with other forms of cancer treatment such as Radio frequency Ablation. The time-length of the radio frequency should be minimum of 45 minutes and more for the treatment to be successful. Since the Radio Frequency Ablation process includes the removal of tissue layers, the treatment proves beneficial when ThermoDox administration follows the frequency treatment.

Celsion Corporation (NASDAQ:CLSN) has known to rally on the stock market, with the successful results ThermoDox achieves. However, it sought further funds in November last from Hercules Growth Capital to meet nearly $20 million requirement that Celsion currently needs. CLSN will seek these funds in graded manner and will begin with the first instalment of $5 million, of which $4 million will be used towards clearly existing loans. The company has sought funds to remain operational on its Heptocellular Carinoma trials which are well into Phase 3 trials as of November end.

Celsion Corporation saw a high rally in the second week of December, when the trail data of the Phase 2, DIGNITY study were reported. According to Dr.Hope Ruog, there were several result parameters which proved to be positive and will help towards moving the drug towards clinical development stages. The application of ThermoDox for different cancers can then be developed, as currently the focus is on the Heptacellular cancer type.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.